Drug Trial Radar · NCT03927716
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
Last checked: Nov 19, 2026Latest source record: Dec 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
352
Actual
Start
Jun 3, 2019
Primary completion
Oct 28, 2019
Study completion Jan 29, 2020
Sponsor
- Lead sponsor
- Novan, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Synteract, Inc.
- First posted
- Apr 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.
Conditions
- Molluscum Contagiosum
Interventions
SB206 12%Drug
Topically once daily
PlaceboDrug
Topically once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Clearance of All Treatable MC at Week 12Time frame: 12 Weeks
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Site #218
Mobile, Alabama
Site #312
Glendale, Arizona
Site #298
Little Rock, Arkansas
Site #272
Rogers, Arkansas
Site #140
Lomita, California
Site #287
Boca Raton, Florida
Site #303
Jacksonville, Florida
Site #264
Miami, Florida
Site #286
Miami Lakes, Florida
Site #273
West Palm Beach, Florida
Site #116
Newnan, Georgia
Site #302
Boise, Idaho
Site #280
Chicago, Illinois
Site #288
Evansville, Indiana
Site #251
Indianapolis, Indiana
Site #117
Louisville, Kentucky
Site #289
Metairie, Louisiana
Site #219
Monroe, Louisiana
Site #308
Silver Spring, Maryland
Site #296
Beverly, Massachusetts
Site #243
Clinton Township, Michigan
Site #279
Greensboro, North Carolina
Site #270
Dublin, Ohio
Site #252
Norman, Oklahoma
Site #237
Gresham, Oregon
Site #311
Warwick, Rhode Island
Site #259
Charleston, South Carolina
Site #295
Fountain Inn, South Carolina
Site #291
Kingsport, Tennessee
Site #183
Austin, Texas
Site #269
Katy, Texas
Site #299
Longview, Texas
Site #224
San Antonio, Texas
Site #277
Salt Lake City, Utah
Site #285
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.